Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Probable inactive ribonuclease-like protein 13 (RNASE13) is a member of the ribonuclease A superfamily, specifically categorized among the non-canonical or non-enzymatically active homologs (RNases 9–13) of this group[1][3][5]. Unlike the canonical RNase A enzymes (RNases 1–8), RNASE13 lacks key sequence elements required for ribonucleolytic (RNA-degrading) activity, and experimental data indicate it is catalytically inactive[1][5][6]. It is expressed primarily in the testes and epididymis and has been hypothesized to play a role in the male reproductive system, possibly linked to sperm maturation or function, but its precise biological function remains unknown[1][3][6]. While some annotation sources assign predicted nucleic acid binding and a possible role in defense against Gram-positive bacteria, there is no direct experimental evidence confirming these roles[6]. RNASE13 has not been validated as a therapeutic target, and no drugs are known to act on it[1][3][6][7]. There are no established biomarker, disease, or safety associations for this protein.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Probable inactive ribonuclease-like protein 13 (RNASE13).